NSRGY Stock Recent News
NSRGY LATEST HEADLINES
Nestle CEO Mark Schneider discusses the impact of GLP-1 drugs on the food industry and the company's products that are tailored to users of the drugs.
CNBC's Silvia Amaro sits down with Nestle CEO Mark Schneider for an exclusive conversation spanning food products, coffee and cocoa prices and the rise of GLP-1 drugs.
The rise of weight loss drugs means consumers' nutritional needs are "shifting," Nestle CEO Mark Schneider told CNBC's Silvia Amaro. Nestle is looking to capitalize on the popularity of the GLP-1 drugs with its "ambitious goal to push the healthier products," the CEO said.
Investors interested in Food - Miscellaneous stocks are likely familiar with Kerry Group PLC (KRYAY) and Nestle SA (NSRGY). But which of these two stocks offers value investors a better bang for their buck right now?
Imagine if, for every cup of coffee you bought, you instead invested that money into coffee stocks. I am not suggesting you stop drinking coffee.
The stock market is at record highs, but the next bear market could be right around the corner. Investors shouldn't become complacent and should be looking for the best defensive stocks to buy.
Nestle (OTCMKTS: NSRGY ) is getting into the weight loss business with new packs of frozen food designed for Ozempic users and others trying to slim down. Nestle is offering these frozen foods for weight loss through its new Vital Pursuit brand.
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss Nestle's new frozen food brand, whether Americans should eat this food, and more.
A new line of frozen foods will cater to users of weight loss drugs like Ozempic and Wegovy. Nestlé's Vital Pursuit brand will include sandwiches and bowls.
Nestle is to launch a new range of cheap frozen pizzas and pasta in the US to tap into the burgeoning market for users of weight loss drugs such as Wegovy and Ozempic. The new products, which will sell for US$5, come with more protein, iron and calcium designed for the appetite-suppressing drugs, called GLP-1 agonists.